This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 Apr;289(16):2071; author reply 2071-2.

doi: 10.1001/jama.289.16.2071-b.

Lipid-lowering therapy and risk of coronary events

Claude K Lardinois

PMID: 12709463
DOI: 10.1001/jama.289.16.2071-b

Comment

Lipid-lowering therapy and risk of coronary events

Claude K Lardinois. JAMA. 2003 Apr.

. 2003 Apr;289(16):2071; author reply 2071-2.

doi: 10.1001/jama.289.16.2071-b.

Author

Claude K Lardinois

PMID: 12709463
DOI: 10.1001/jama.289.16.2071-b

No abstract available

PubMed Disclaimer

Comment on

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002 Dec 18;288(23):2998-3007. doi: 10.1001/jama.288.23.2998. JAMA. 2002. PMID: 12479764 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information